Relevant bibliographies by topics / Hypertension portopulmonaire

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Hypertension portopulmonaire'

Author: Grafiati
Published: 25 January 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hypertension portopulmonaire.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hypertension portopulmonaire"

1

Chabot, F., E. Gomez, L. Boyer, A. Kheir, J. Le Pavec, O. Sitbon, and P. Herve. "Hypertension portopulmonaire." Revue des Maladies Respiratoires 23, no. 6 (December 2006): 629–41. http://dx.doi.org/10.1016/s0761-8425(06)72078-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Magois, E., J. C. Glerant, I. Mayeux, B. Toublanc, D. Mispelaere, and V. Jounieaux. "134 Hypertension artérielle portopulmonaire (HTTP) et opacités pseudotumorales." Revue des Maladies Respiratoires 21 (January 2004): 61. http://dx.doi.org/10.1016/s0761-8425(04)71760-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Halim, A., A. O. Daher, M. N. Guèye, S. Diallo, M. Bodian, M. P. Fall, M. A. Thioubou, M. L. Bassène, S. Fall, and M. L. Diouf. "Hypertension portopulmonaire révélant une cirrhose d’origine auto-immune : à propos d’un cas." Journal Africain d'Hépato-Gastroentérologie 10, no. 4 (September 16, 2016): 217–19. http://dx.doi.org/10.1007/s12157-016-0677-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Saleemi, Sarfraz. "Portopulmonary hypertension." Annals of Thoracic Medicine 5, no. 1 (2010): 5. http://dx.doi.org/10.4103/1817-1737.58953.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hopps, Eugenia, Amelia Valenti, and Gregorio Caimi. "Portopulmonary Hypertension." Clinical & Investigative Medicine 34, no. 3 (June 1, 2011): 111. http://dx.doi.org/10.25011/cim.v34i3.15182.

Full text
Abstract:
Portopulmonary hypertension (PPHT) is a respiratory complication of portal hypertension, defined as an increase in mean pulmonary artery pressure (PAP) of > 25 mmHg with an increase in pulmonary vascular resistance of > 240 dyn.s/cm-5 and a normal pulmonary capillary wedge pressure ( < 15 mmHg), which often occurs in subjects with liver cirrhosis. Histopathological features of PPHT are endothelial and smooth-muscle cell proliferation and fibrosis leading to luminal obstruction in the resistance arteries. The pathogenesis of PPHT may result from an imbalance between vasoconstrictor and vasodilating factors. The most common pulmonary symptom is exertional dyspnea; fatigue, chest pain and syncope occur more often at an advanced stage. Edema, ascites and prominent jugular veins are signs of both decompensated hepatic cirrhosis and right ventricular failure. Right heart catheterisation is the gold standard for the diagnosis and defines PPHT in mild disease with PAP less than 35 mmHg, moderate disease with PAP between 35 and 45 mmHg, and severe disease with PAP of 45 mmHg or higher. The medical treatment of portopulmonary hypertension is based on the treatment of other forms of pulmonary arterial hypertension, including vasomodulating pharmacologic agents. Liver transplantation is accompanied by high risk of mortality, generally due to acute right ventricular failure and cardiovascular collapse. The prognosis of PPHT is poor with mean survival of 15 months.
APA, Harvard, Vancouver, ISO, and other styles
6

Lv, Yong, Guohong Han, and Daiming Fan. "Portopulmonary hypertension." Scandinavian Journal of Gastroenterology 51, no. 7 (March 22, 2016): 795–806. http://dx.doi.org/10.3109/00365521.2016.1157895.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mukhtar, Nizar A., and Oren K. Fix. "Portopulmonary Hypertension." Journal of Clinical Gastroenterology 45, no. 8 (September 2011): 703–10. http://dx.doi.org/10.1097/mcg.0b013e31820656bd.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Le Pavec, Jérôme, Rogério Souza, Philippe Herve, Didier Lebrec, Laurent Savale, Colas Tcherakian, Xavier Jaïs, et al. "Portopulmonary Hypertension." American Journal of Respiratory and Critical Care Medicine 178, no. 6 (September 15, 2008): 637–43. http://dx.doi.org/10.1164/rccm.200804-613oc.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Watherald, Jason, Olivier Sitbon, and Laurent Savale. "Portopulmonary Hypertension." Seminars in Respiratory and Critical Care Medicine 38, no. 05 (October 2017): 651–61. http://dx.doi.org/10.1055/s-0037-1606251.

Full text
Abstract:
AbstractPortal hypertension may have major consequences on the pulmonary vasculature due to complex pathophysiological interactions between liver and lungs. Portopulmonary hypertension (PoPH) is characterized by the association of portal hypertension and pulmonary arterial hypertension (PAH). As progressive elevation of right ventricular afterload can lead to right heart failure, PoPH is a serious complication of portal hypertension, affecting functional status and prognosis of patients. Early detection by transthoracic echocardiography must be performed in symptomatic patients and in candidates for liver transplantation (LT). Right heart catheterization remains mandatory to confirm the diagnosis and exclude all other causes of elevated pulmonary pressures. The management of PoPH includes PAH-targeted therapies although few studies have evaluated these medications in this specific indication. The impact of LT on PoPH outcome remains complex and must be specified by future collaborative investigation. Although uncontrolled PoPH is associated with higher risk of postoperative right heart failure and death, stabilization, improvement, or normalization of pulmonary hemodynamics after LT seem to be achievable goals in selected patients with PoPH.
APA, Harvard, Vancouver, ISO, and other styles
10

DuBrock, Hilary M., Reena J. Salgia, Norman L. Sussman, Sonja D. Bartolome, Zakiyah Kadry, David C. Mulligan, Sarah Jenkins, et al. "Portopulmonary Hypertension." Transplantation Direct 5, no. 6 (June 2019): e456. http://dx.doi.org/10.1097/txd.0000000000000900.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hypertension portopulmonaire"

1

Le, Pavec Jérôme. "Hypertension portopulmonaire : aspects cliniques et biologiques." Paris 11, 2008. http://www.theses.fr/2008PA11T026.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Robert, Fabien. "Étude du BMP-9 et du PlGF dans la physiopathologie du syndrome hépatopulmonaire : À la recherche de cibles thérapeutiques." Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASQ054.

Full text
Abstract:
Le syndrome hépatopulmonaire (SHP) est une complication pulmonaire sévère provoquée par différentes maladies du foie. Il se caractérise par une prolifération et une dilatation anormale des petits vaisseaux sanguins dans les poumons, ce qui réduit l'oxygénation du sang. Actuellement, la transplantation hépatique est la seule solution pour traiter cette maladie. Il est essentiel de mieux comprendre les mécanismes impliqués dans le développement et l'aggravation du SHP pour développer des traitements plus efficaces. Dans le cadre de cette thèse, nous avons exploré deux cibles thérapeutiques prometteuses. La première est le BMP-9, dont la perte est indispensable dans le développement de la pathologie. La deuxième est le PlGF, dont la surproduction en cas de cirrhose aggrave les défauts d'oxygénation du sang. Ces deux nouvelles pistes pourraient permettre de mettre au point des traitements plus ciblés pour le SHP
Hepatopulmonary syndrome (HPS) is a severe pulmonary complication caused by liver diseases. It is characterized by abnormal proliferation and dilation of the small blood vessels in the lungs, leading to reduced blood oxygenation. Currently, liver transplantation is the only available treatment for this condition. Understanding the mechanisms involved in both the development and progression of HPS is crucial for developing more effective treatments. During this PhD, we explored two promising therapeutic targets. The first is BMP-9, a protein whose loss is necessary for the development of the disease. The second is PlGF, a protein that increases specifically in the context of cirrhosis and can worsen blood oxygenation issues. These new avenues could lead to the development of more targeted treatments for HPS
APA, Harvard, Vancouver, ISO, and other styles
3

Shimozono, Emica 1962. "Estudo retrospectivo da prevalência da hipertensão portopulmonar, complicações intraoperatórias e sobrevida em pacientes submetidos a transplante de fígado." [s.n.], 2014. http://repositorio.unicamp.br/jspui/handle/REPOSIP/312715.

Full text
Abstract:
Orientadores: Ilka de Fátima Santana Ferreira Boin, Cristina Aparecida Arrivabene Caruy
Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas
Made available in DSpace on 2018-08-24T17:26:07Z (GMT). No. of bitstreams: 1 Shimozono_Emica_M.pdf: 4271192 bytes, checksum: ec937b4448d3157cccab1d06c8b5a8d3 (MD5) Previous issue date: 2014
Resumo: A Hipertensão Portopulmonar (HPP) é caracterizada pelo desenvolvimento da hipertensão arterial pulmonar associada à hipertensão portal, com ou sem doença hepática. É definida como pressão arterial pulmonar média (PAPM) acima de 25 mmHg, resistência vascular pulmonar (RVP) acima de 240 dinas.s.cm?? e a pressão de oclusão da artéria pulmonar (POAP) normal, menor de 15 mmHg. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo a sua prevalência estimada entre 2 - 6%. A mortalidade é diretamente proporcional à medida da pressão arterial pulmonar média e da resistência vascular pulmonar. Alguns estudos sugerem que a pressão da artéria pulmonar média pré-operatória seja um preditor independente para mortalidade, e muitos centros consideram que pressão arterial pulmonar média acima de 50 mmHg seja uma contraindicação absoluta para o transplante de fígado (TF). Objetivo: Analisar a prevalência, as complicações e a sobrevida dos pacientes portadores de HPP submetidos a transplante de fígado. Método: Foram analisados de modo retrospectivo, prontuários e o banco de dados da Unidade de Transplante Hepático do Hospital de Clínicas da Universidade Estadual de Campinas dos pacientes submetidos a transplante de fígado, num período de 21 anos. Dividiu-se a população em dois grupos de acordo com as medidas da pressão da artéria pulmonar média: PAPM ? 25 mmHg e PAPM > 25 mmHg. Foram estudados os exames pré-operatórios, as variáveis hemodinâmicas, bem como as complicações intraoperatórias, eventos relacionados e a sobrevida. Resultado: Foram encontrados 50 casos com PAPM > 25 mmHg e apenas um caso preencheu os critérios diagnósticos de PAPM > 25 mmHg, RVP > 240 dinas.s.cm-5 e POAP < 15 mmHg , de acordo com a European Respiratory Society Task Force on Pulmonary Hepatic Vascular Disorders (2004), e dois casos de PAPM > 50 mmHg que tiveram os procedimentos suspensos, portanto a nossa prevalência da HPP em pacientes submetidos a TF foi de 0,25%. As complicações intraoperatórias foram semelhantes nos dois grupos. A sobrevida no grupo PAPM > 25 mmHg foi menor que no grupo PAPM ? 25 mmHg. Conclusão: A prevalência da HPP observada foi menor que a descrita na literatura, ou seja, 50 (12,9%) pacientes apresentaram PAPM > 25 mmHg, sendo que destes, 49 (12,6%) apresentaram resistência vascular pulmonar < 240 dinas.s.cm-5, portanto sem HPP, e provavelmente tratava-se de circulação hiperdinâmica e/ou sobrecarga de volume. O fato de o paciente apresentar pressão arterial pulmonar média maior que 25 mmHg, não influenciou na sobrevida do enxerto
Abstract: Portopulmonary hypertension (PPH) is characterized by the development of pulmonary artery hypertension associated with portal hypertension, with or without liver disease. It is defined as a mean pulmonary artery pressure (MPAP) above 25 mmHg, pulmonary vascular resistance (PVR) above 240 dynes.s.cm-5 and the pulmonary capillary wedge pressure (PCWP) normal under 15 mmHg. The association of pulmonary hypertension with cirrhosis and portal hypertension is underdiagnosed, with an estimated prevalence of two to 6%. The mortality is directly proportional to the measured mean pulmonary artery pressure and pulmonary vascular resistance. Some studies suggest that the mean pulmonary artery pressure preoperatively is an independent predictor for mortality, and many centers consider that the mean pulmonary artery pressure above 50 mmHg is one absolute contraindication for liver transplantation (LT). Objective: To analyze the PPH prevalence, complications and survival in patients undergoing liver transplantation. Method: We analyzed retrospectively, records and data base from the Liver Transplantation Unit of the Clinical Hospital of UNICAMP of patients undergoing liver transplantation, a 21 year period. The population was separated into two groups according to the measurements of mean pulmonary artery pressure: MPAP ? 25 mmHg and MPAP > 25 mmHg. We studied the preoperative examinations, hemodynamic variables, as well as intraoperative complications, related events to PPH and survival. Result: We found 50 cases with MPAP > 25 mmHg, and one case met the diagnostic criteria for MPAP > 25 mmHg, PVR > 240 dynes.s.cm-5 and PCWP < 15 mmHg, according to European Respiratory Society Task Force on Pulmonary Hepatic Vascular Disorders (2004), and two cases of MPAP > 50 mmHg who had the procedure canceled, so our PPH prevalence in patients undergoing LT was 0,25%. The intraoperative complications were similar in both groups. The survival in group MPAP > 25 mmHg was lower than in group MPAP ? 25 mmHg. Conclusion: The prevalence rate observed was lower than described in literature, that is, 50 (12,9%) patients showed MPAP > 25 mmHg, and 49 (12,6%) of these patients had pulmonary vascular resistance < 240 dynes.s.cm-5 and therefore no PPH. This was probably due to hyperdynamic circulation and/or volume overload. The fact that mean pulmonary artery pressure was > 25 mmHg in these patients had no influence on graft survival
Mestrado
Fisiopatologia Cirúrgica
Mestra em Ciências
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Hypertension portopulmonaire"

1

Cartin-Ceba, Rodrigo, and Michael J. Krowka. "Portopulmonary Hypertension." In Complications of Cirrhosis, 177–86. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13614-1_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Cartin-Ceba, Rodrigo, and Michael J. Krowka. "Portopulmonary hypertension." In Cirrhosis: A practical guide to management, 212–24. Chichester, UK: John Wiley & Sons, Ltd, 2015. http://dx.doi.org/10.1002/9781118412640.ch19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ahmad, Jawad. "Portopulmonary Hypertension." In Mount Sinai Expert Guides: Hepatology, 263–70. Oxford, UK: John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118748626.ch24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cartin-Ceba, Rodrigo, Vivek N. Iyer, and Michael J. Krowka. "Hepatopulmonary Syndrome and Portopulmonary Hypertension." In Contemporary Liver Transplantation, 1–23. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-05543-5_10-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cartin-Ceba, Rodrigo, Vivek N. Iyer, and Michael J. Krowka. "Hepatopulmonary Syndrome and Portopulmonary Hypertension." In Contemporary Liver Transplantation, 1–24. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-05543-5_10-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Kochar, Rajan, and Michael B. Fallon. "Hepatopulmonary syndrome and portopulmonary hypertension." In Textbook of Clinical Gastroenterology and Hepatology, 751–56. Oxford, UK: Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781118321386.ch101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ramsay, Michael. "Portopulmonary Hypertension and Hepatopulmonary Syndrome." In Anesthesia and Perioperative Care for Organ Transplantation, 427–39. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6377-5_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Savale, Laurent, Philippe Hervé, and Olivier Sitbon. "Portopulmonary Hypertension and Hepatopulmonary Syndrome." In Pulmonary Vascular Disorders, 113–21. Basel: S. KARGER AG, 2012. http://dx.doi.org/10.1159/000335090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cartin-Ceba, Rodrigo, Vivek N. Iyer, and Michael J. Krowka. "Hepatopulmonary Syndrome and Portopulmonary Hypertension." In Contemporary Liver Transplantation, 189–209. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-07209-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Okajima, Hideaki. "Long-Term Complications: Portopulmonary Hypertension." In Introduction to Biliary Atresia, 247–54. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-2160-4_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hypertension portopulmonaire"

1

Savale, Laurent, Romain Magnier, Jérôme Le Pavec, Dermot S. O'Callaghan, Xavier Jaïs, Delphine Natali, Marc J. C. Humbert, Gerald Simonneau, and Olivier Sitbon. "Impact Of Pulmonary Arterial Hypertension Specific Therapy On Portopulmonary Hypertension." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3339.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Connolly, M., R. J. White, and D. Lachant. "Resolution of Portopulmonary Hypertension After Liver Transplantation." In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chickmagalur, S., K. Reiling, C. Chartan, N. P. Varghese, N. M. Villafranco, and R. Coleman. "Atypical Pediatric Presentation of Severe Portopulmonary Hypertension." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2287.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Randhawa, S., E. Griffin, M. Dhingra, M. Hiatt, J. Alberts, V. V. Noble, and A. Highley. "Portopulmonary Hypertension: A Case Report with Management Considerations." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6788.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jevnikar, Mitja, Nathan Ebstein, Xavier Jais, Athenais Boucly, David Montani, Marc Humbert, Olivier Sitbon, and Laurent Savale. "Efficacy and safety of tadalafil in portopulmonary hypertension." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa3050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gregonis, Erica L., Gregory R. White, Alex G. Duarte, Nahal Boroumand, and Abida Haque. "Prevalence Of Portopulmonary Hypertension: A Clinico-Pathologic Assessment." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1922.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mai, E., J. Gomez-Arroyo, A. Pillai, C. Zhou, K. Snapp, S. Demetrio, D. Kay, et al. "CT-derived vascular pruning assessment in portopulmonary hypertension." In ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.1526.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Le Pavec, J., B. Girerd, D. Montani, F. Perros, L. Savale, G. Simonneau, O. Sitbon, and M. Humbert. "Circulating Dendritic Cells in Idiopathic Pulmonary Arterial Hypertension and Cirrhotic Portopulmonary Hypertension." In American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California. American Thoracic Society, 2009. http://dx.doi.org/10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a4289.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Lacoste-Palasset, Thomas, Antoine Beurnier, Audrey Baron, Marie-Caroline Certain, Xavier Jaïs, Anne Roche, David Montani, Marc Humbert, Olivier Sitbon, and Laurent Savale. "Impact of pulmonary arterial hypertension therapies on gas exchange in portopulmonary hypertension." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa1766.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Spyropoulos, J., G. Boutsalis, and K. Hanley. "Improving Management of Portopulmonary Hypertension: Effectiveness of Online CME." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3777.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hypertension portopulmonaire' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography